NEW YORK , July 13, 2022  /PRNewswire/ -- The National Advertising Division (NAD) of BBB National Programs recommended that Sanofi Consumer Healthcare discontinue "#1 doctor recommended" claims for its Zantac 360° heartburn medicine. Sanofi will appeal NAD's decision.

The claims, which appeared on Sanofi's social media pages, the websites of third-party retailers, and in a television commercial, were challenged by Johnson & Johnson Consumer, Inc., manufacturer of competing Pepcid products.

The parties manufacture and market the leading brands of OTC heartburn medication in a category called Histamine-2 (H2) Blockers which prevent and relieve heartburn by reducing stomach acid. H2 blockers are indicated for mild to occasional heartburn or indigestion.

In 2020, Sanofi introduced Zantac 360°, an H2 blocker formulated with the active ingredient famotidine - the same active ingredient used in the challenger's Pepcid products.

NAD determined that one reasonable message conveyed by the challenged claims that Zantac 360° "contains the #1 doctor recommended medicine approved to both prevent and relieve heartburn" and "with the #1 doctor recommended heartburn medicine" is that Zantac 360° is the #1 doctor recommended product or brand to prevent and relieve heartburn. In so finding, NAD disagreed with the advertiser's contention that the challenged advertising clearly refers to Zantac's active ingredient.

NAD came to the same conclusion regarding the "#1 doctor recommended" claim in various iterations of the Google Ads appearing in search results for Zantac 360°. NAD determined that in the absence of anything grammatically or syntactically tying "#1 doctor recommended" to the ingredient famotidine or otherwise qualifying the claim, one message reasonably conveyed by the Google Ads is that Zantac 360° is the #1 doctor recommended product for heartburn.

As support for its claims, the advertiser relied on the results of IQVIA survey data that documented physicians' average weekly recommendations in the acid reducer category. Although NAD considered whether this data could substantiate modified claims that Zantac 360° contains famotidine which, among H2 blockers, is the #1 doctor recommended ingredient to prevent and relieve heartburn, NAD concluded that it was inadequate support. NAD noted that ingredient-level data cannot be used to support product-level claims and that this same principle applies in reverse. NAD agreed with the challenger that although famotidine-based products received most doctor recommendations in the H2 category, these facts were not a viable substitute for an affirmative active ingredient recommendation and fell short of the evidence required to support a "#1 doctor recommended" claim.

NAD also concluded that data from a single run question in the March monthly survey directed to active ingredient recommendations in the acid reducer category did not support claims that Zantac 360° contained the #1 doctor recommended ingredient to prevent and treat heartburn. Although a majority of doctors who responded with an H2 blocker choice selected famotidine as the ingredient they recommend most, NAD noted the recommendations were expressly directed to "frequent heartburn" – a specific, clinically meaningful kind of heartburn and one that is distinct from the indication stated in the challenged claims, e.g., "to prevent and relieve heartburn."

For these reasons, NAD recommended that the advertiser discontinue the claims:

Zantac 360° "contains the #1 doctor recommended medicine approved to both prevent and relieve heartburn."

"With the #1 doctor recommended heartburn medicine."

In its advertiser statement, Sanofi stated that it will appeal NAD's decision because it "disagrees with NAD's conclusions that the underlying IQVIA survey cannot substantiate doctor recommended ingredient claims" and because it "has concerns about the downstream industry-wide ramifications" of this finding. The advertiser further stated that although it "respectfully disagrees" with NAD's conclusions regarding the "contains the #1 doctor recommended medicine" claim, it will "nevertheless take the NAD's recommendations with respect to this ruling into consideration in future advertising."

Appeals of NAD decisions are made to BBB National Programs' National Advertising Review Board (NARB), the appellate-level truth-in-advertising body of BBB National Programs.

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive.

BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019 , BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.

About the National Advertising Division:

The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.

View original content to download multimedia:https://www.prnewswire.com/news-releases/national-advertising-division-recommends-sanofi-discontinue-1-doctor-recommended-claims-for-zantac-360-sanofi-to-appeal-301585434.html

The deal talks are still on track but coming data and arbitration slowed the timeline, people familiar with the matter say.

The top five biotech stocks today have several commonalities: strong ratings, promising charts and membership on the IBD Tech Leaders list.

YouTube: NBC10 RochesterA Rochester police officer is on desk duty after he was caught on camera forcefully handcuffing an emergency medical technician who’d reportedly bumped his squad car with her ambulance door just outside a hospital.According to News 10 Rochester, the Monroe Ambulance EMT was attempting to unload a patient in the ambulance bay area at Strong Memorial Hospital when she hit the cop’s car. The officer then demanded the EMT give him her identification, but the health-care worke

The FDA authorized Novavax's Covid vaccine for emergency use, but NVAX stock tumbled on Thursday on warnings facing the two-dose regimen.

Novavax Inc. can finally celebrate after earning a long-awaited green light for its Covid-19 vaccine. The Gaithersburg vaccine maker saw its share price plummet more than 28% Thursday, an unexpected reaction after the Food and Drug Administration granted the company’s product emergency use authorization for primary immunization in adults. About 250,000 doses of Novavax’s vaccine had been administered in Europe since December, according to the European Centre for Disease Prevention and Control.

Companies with interests in approved drugs or late-stage drugs can draw cash immediately by selling their sales-based royalty streams.

The 6-year-old was bitten while at the Bluestem Prairie Open Space near Colorado Springs on July 5 and died Monday.

Men in the United States are sicker and more likely to die early from preventable causes compared with their peers in other similarly high-income countries, a new study has found.

If the county remains at the high community level for the next two weeks, a new masking order would be issued, with an effective date of July 29.

Class action suit says Mars concealed information about toxic ingredient from consumers

(Bloomberg) -- Senate Democrats plan to introduce a bill to decriminalize marijuana at the federal level next week, a person familiar with the matter said, although the legislation faces long odds in the evenly divided chamber.Most Read from BloombergIvana Trump, First Wife of Former President, Dies At 73Chinese Homebuyers Across 22 Cities Refuse to Pay MortgagesWall Street Texting Habit Sticks Banks With Rare $1 Billion BillChina Growth Slows Sharply, Putting GDP Target Out of ReachMajority Lea

The doctor at the center of a firestorm over abortion rights sent a cease and desist letter to Indiana Attorney General Todd Rokita on Friday.

IU Health officials say investigation did not find any violations on the part of Dr. Caitlin Bernard.

A group of House progressives led by Reps. Alexandria Ocasio-Cortez (D-N.Y.) and Mondaire Jones (D-N.Y.) called on House Speaker Nancy Pelosi (D-Calif.) and Senate Majority Leader Charles Schumer (D-N.Y.) to strip the Supreme Court of its abortion jurisdiction. “We write to urge your support for restricting the Supreme Court’s appellate jurisdiction in the areas of…

The Federal Drug Administration granted emergency use authorization for the Novavax COVID-19 vaccine.

Only five people are known surivors of rare disease

The case of a 10-year-old rape victim is highlighting the election downsides of the new wave of abortion bans.

The Covid-19 booster programme has been extended to include all over-50s from September, amid fears of a double threat this winter from the omicron variant and flu.

Patients with long COVID may see some improvement after breathing pure oxygen in a high-air-pressure environment, according to data from a small Israeli trial. Researchers randomly assigned 73 patients with post-COVID symptoms lasting at least three months to receive hyperbaric oxygen therapy (HBOT) or a sham treatment. Patients in the HBOT group spent 40 sessions breathing pure oxygen in a chamber in which the air pressure was two-to-three times higher than normal, allowing the lungs to receive more oxygen than they normally would.

If you feel sad and alone, know there are many ways to reconnect. We talked to doctors, therapists, and researchers about some of the best strategies to cope.